iRhythm completes $237.5m VitalConnect acquisition

iRhythm has closed its purchase of wearable biosensor firm VitalConnect for $237.5m, extending its cardiac monitoring reach into inpatient and hospital-to-home settings.

The Biotech Times Editorial Team By The Biotech Times Editorial Team AI level 2 of 5
AI level 2 of 5: drafted by our AI editorial assistant from the company's announcement; fact-checked, edited and signed off by Mark Walker, Editorial Director. What the levels mean
A modern conference room features a long wooden table set with stacks of papers and pens, surrounded by chairs, and brightly lit by natural light from large windows, revealing dust particles in the air.

iRhythm Holdings has completed its acquisition of VitalConnect, a wearable biosensor and ambulatory cardiac monitoring company, for $237.5 million in cash plus up to 423,334 shares issued at closing. The NASDAQ-listed company also provided $10 million in working capital funding to VitalConnect between signing and closing, subject to customary adjustments.

The deal brings VitalConnect's mobile cardiac telemetry (MCT) platform into iRhythm's portfolio alongside its established Zio wearable biosensor and cloud-based analytics service. iRhythm said it expects the transaction to enhance its revenue growth rate from 2027 onwards while preserving its previously communicated 15% adjusted EBITDA margin target for that year. Updated 2026 financial guidance incorporating VitalConnect is expected at the company's third-quarter earnings call on 5 November.

What VitalConnect adds

VitalConnect's platform supports monitoring of up to 11 physiological parameters over periods of up to 30 days, a four-in-one functional architecture, and what the company describes as a "live look-in" capability for remote clinical oversight. That multi-vitals scope goes beyond the traditional single-lead or patch-based ambulatory ECG monitoring that has historically defined iRhythm's Zio product line.

Quentin Blackford, president and chief executive of iRhythm, said the combination would allow the company to "offer clinicians greater choice, serve more patients and customers across the continuum of care, and deepen customer relationships." Peter Van Haur, chief executive of VitalConnect, said joining iRhythm would "accelerate the growth of our platform" and expand patient access.

The deal also extends iRhythm's addressable market into inpatient and hospital-to-home monitoring, settings that have historically been served by larger capital-equipment vendors rather than patch-based wearables companies.

Market context and competitive read-across

The ambulatory cardiac monitoring market has been consolidating steadily, driven by rising atrial fibrillation detection demand, expanded reimbursement for long-duration ECG patches, and growing payer interest in remote patient management that reduces inpatient stays. iRhythm's Zio patch has commanded strong market share in extended Holter monitoring, but the company has faced competition from MCT-focused players and from broader remote patient monitoring platforms offered by larger medtech groups.

By acquiring VitalConnect's MCT and multi-vitals capabilities, iRhythm is positioning itself to compete across a wider range of cardiac monitoring categories rather than defending a single-modality niche. The hospital-to-home angle is particularly significant: health systems have been under sustained pressure to discharge patients earlier, creating demand for monitoring solutions that bridge acute and community settings. Several large medtech companies have moved into this corridor, and iRhythm's combined platform may allow it to compete for hospital enterprise contracts that its patch-only offering could not previously target.

Integration execution will be the near-term test. Cross-selling into iRhythm's existing health system relationships represents the clearest synergy opportunity, but MCT services carry different reimbursement and clinical workflow requirements from ambulatory ECG patches, and aligning those commercial models will take time. Investors will look to the November earnings call for management's quantified revenue contribution estimate and for any update to the integration roadmap.

Sector

Topic

Geography